Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;42(7):1054-9.
doi: 10.1097/MPA.0b013e3182965a3c.

Metformin and survival in pancreatic cancer: a retrospective cohort study

Affiliations

Metformin and survival in pancreatic cancer: a retrospective cohort study

Allen L Hwang et al. Pancreas. 2013 Oct.

Abstract

Objectives: Our aim was to determine the effect of metformin exposure on survival in patients with advanced pancreatic adenocarcinoma (PAC).

Methods: A retrospective cohort study was conducted using The Health Improvement Network, a primary care electronic medical record database from the United Kingdom (2003-2010). The study cohort included all subjects with a diagnostic code for incident PAC and a preexisting diagnosis of type 2 diabetes mellitus. Subjects were classified as exposed if they were prescribed metformin around the time of PAC diagnosis (between 6 months prior and 1 month after). A secondary analysis was performed only on exposed subjects without prior (ie, 6 months before PAC diagnosis) exposure to metformin. The primary outcome was overall survival. The analysis was performed using univariate and multivariable Cox proportional hazards models.

Results: The study included 516 subjects with preexisting type 2 diabetes mellitus and PAC, 247 of which were exposed to metformin. In univariate and multivariable analysis, there was no difference in survival between those exposed and those unexposed to metformin in the primary analysis (hazards ratio, 1.11 [0.89-1.38], P = 0.367) or the secondary analysis (hazards ratio, 1.09 [0.80-1.47], P = 0.585).

Conclusions: Metformin use is not associated with improved survival in subjects with advanced PAC.

PubMed Disclaimer

Conflict of interest statement

There are no financial disclosures or conflicts of interest.

Figures

Figure 1
Figure 1
Inclusion/exclusion criteria, flow diagram.
Figure 2
Figure 2
Kaplan-Meier Curves for Survival in the As-Treated Analysis.

Similar articles

Cited by

References

    1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. - PubMed
    1. Howlader NNA, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975–2008.
    1. Jimenez RE, Fernandez-del Castillo C. Pancreatic Cancer. 9. 2010.
    1. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–5518. - PubMed
    1. Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003;14(1):97–104. - PubMed

Publication types

MeSH terms